458 related articles for article (PubMed ID: 20048174)
1. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.
Wagner AJ; Malinowska-Kolodziej I; Morgan JA; Qin W; Fletcher CD; Vena N; Ligon AH; Antonescu CR; Ramaiya NH; Demetri GD; Kwiatkowski DJ; Maki RG
J Clin Oncol; 2010 Feb; 28(5):835-40. PubMed ID: 20048174
[TBL] [Abstract][Full Text] [Related]
2. Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates.
Dickson MA; Schwartz GK; Antonescu CR; Kwiatkowski DJ; Malinowska IA
Int J Cancer; 2013 Apr; 132(7):1711-7. PubMed ID: 22927055
[TBL] [Abstract][Full Text] [Related]
3. A rare metastatic mesenteric malignant PEComa with TSC2 mutation treated with palliative surgical resection and nab-sirolimus: a case report.
Meredith L; Chao T; Nevler A; Basu Mallick A; Singla RK; McCue PA; Bowne WB; Jiang W
Diagn Pathol; 2023 Apr; 18(1):45. PubMed ID: 37041531
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Advanced Malignant Uterine Perivascular Epithelioid Cell Tumor with mTOR Inhibitors: Single-institution Experience and Review of the Literature.
Starbuck KD; Drake RD; Budd GT; Rose PG
Anticancer Res; 2016 Nov; 36(11):6161-6164. PubMed ID: 27793946
[TBL] [Abstract][Full Text] [Related]
5. Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa.
Italiano A; Delcambre C; Hostein I; Cazeau AL; Marty M; Avril A; Coindre JM; Bui B
Ann Oncol; 2010 May; 21(5):1135-7. PubMed ID: 20215136
[No Abstract] [Full Text] [Related]
6. First pancreatic perivascular epithelioid cell tumor (PEComa) treated by mTOR inhibitor.
Gondran H; Thebaud E; Moreau A; Le Rhun M; Touchefeu Y; Regenet N; Musquer N
Pancreatology; 2019 Jun; 19(4):566-568. PubMed ID: 31130397
[TBL] [Abstract][Full Text] [Related]
7. Constant allelic alteration on chromosome 16p (TSC2 gene) in perivascular epithelioid cell tumour (PEComa): genetic evidence for the relationship of PEComa with angiomyolipoma.
Pan CC; Chung MY; Ng KF; Liu CY; Wang JS; Chai CY; Huang SH; Chen PC; Ho DM
J Pathol; 2008 Feb; 214(3):387-93. PubMed ID: 18085521
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant or adjuvant sirolimus for malignant metastatic or locally advanced perivascular epithelioid cell tumors: two case reports.
Batereau C; Knösel T; Angele M; Dürr HR; D'Anastasi M; Kampmann E; Ismann B; Bücklein V; Lindner LH
Anticancer Drugs; 2016 Mar; 27(3):254-8. PubMed ID: 26645891
[TBL] [Abstract][Full Text] [Related]
9. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth.
Shaw RJ
Acta Physiol (Oxf); 2009 May; 196(1):65-80. PubMed ID: 19245654
[TBL] [Abstract][Full Text] [Related]
10. Dampened VEPH1 activates mTORC1 signaling by weakening the TSC1/TSC2 association in hepatocellular carcinoma.
Dong P; Wang X; Liu L; Tang W; Ma L; Zeng W; Sun S; Zhang L; Zhang N; Shen X; Janssen HLA; Dong L; Zhang S; Chen S
J Hepatol; 2020 Dec; 73(6):1446-1459. PubMed ID: 32610114
[TBL] [Abstract][Full Text] [Related]
11. A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experience.
Benson C; Vitfell-Rasmussen J; Maruzzo M; Fisher C; Tunariu N; Mitchell S; Al-Muderis O; Thway K; Larkin J; Judson I
Anticancer Res; 2014 Jul; 34(7):3663-8. PubMed ID: 24982384
[TBL] [Abstract][Full Text] [Related]
12. Smooth muscle protein-22-mediated deletion of Tsc1 results in cardiac hypertrophy that is mTORC1-mediated and reversed by rapamycin.
Malhowski AJ; Hira H; Bashiruddin S; Warburton R; Goto J; Robert B; Kwiatkowski DJ; Finlay GA
Hum Mol Genet; 2011 Apr; 20(7):1290-305. PubMed ID: 21212099
[TBL] [Abstract][Full Text] [Related]
13. Molecular pathology of lymphangioleiomyomatosis and other perivascular epithelioid cell tumors.
Martignoni G; Pea M; Reghellin D; Gobbo S; Zamboni G; Chilosi M; Bonetti F
Arch Pathol Lab Med; 2010 Jan; 134(1):33-40. PubMed ID: 20073603
[TBL] [Abstract][Full Text] [Related]
14. Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors.
Sanfilippo R; Fabbroni C; Fucà G; Fumagalli E; Morosi C; Sbaraglia M; Gronchi A; Collini P; Dei Tos AP; Casali PG
Clin Cancer Res; 2020 Oct; 26(20):5534-5538. PubMed ID: 32605908
[TBL] [Abstract][Full Text] [Related]
15. Effective Therapeutic Intervention and Comprehensive Genetic Analysis of mTOR Signaling in PEComa: A Case Report.
Weeber F; Koudijs MJ; Hoogstraat M; Besselink NJ; VAN Lieshout S; Nijman IJ; Cuppen E; Offerhaus GJ; Voest EE
Anticancer Res; 2015 Jun; 35(6):3399-403. PubMed ID: 26026101
[TBL] [Abstract][Full Text] [Related]
16. TFE3 activation in a TSC1-altered malignant PEComa: challenging the dichotomy of the underlying pathogenic mechanisms.
Schmiester M; Dolnik A; Kornak U; Pfitzner B; Hummel M; Treue D; Hartmann A; Agaimy A; Weyerer V; Lekaj A; Brakemeier S; Peters R; Öllinger R; Märdian S; Bullinger L; Striefler JK; Flörcken A
J Pathol Clin Res; 2021 Jan; 7(1):3-9. PubMed ID: 33180365
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment with the mTOR inhibitor everolimus in a patient with perivascular epithelioid cell tumor.
Gennatas C; Michalaki V; Kairi PV; Kondi-Paphiti A; Voros D
World J Surg Oncol; 2012 Sep; 10():181. PubMed ID: 22943457
[TBL] [Abstract][Full Text] [Related]
18. Medical treatment of advanced malignant perivascular epithelioid cell tumors.
Fabbroni C; Sbaraglia M; Sanfilippo R
Curr Opin Oncol; 2020 Jul; 32(4):301-306. PubMed ID: 32541317
[TBL] [Abstract][Full Text] [Related]
19. Stromal liver kinase B1 [STK11] signaling loss induces oviductal adenomas and endometrial cancer by activating mammalian Target of Rapamycin Complex 1.
Tanwar PS; Kaneko-Tarui T; Zhang L; Tanaka Y; Crum CP; Teixeira JM
PLoS Genet; 2012; 8(8):e1002906. PubMed ID: 22916036
[TBL] [Abstract][Full Text] [Related]
20. Heterozygous inactivation of tsc2 enhances tumorigenesis in p53 mutant zebrafish.
Kim SH; Kowalski ML; Carson RP; Bridges LR; Ess KC
Dis Model Mech; 2013 Jul; 6(4):925-33. PubMed ID: 23580196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
